Abstract

High-dose chemotherapy and autologous stem cell transplantation (SCT) or allogeneic SCT can lead to durable remissions in patients with hematologic malignancies. In the mid-1980s the first studies demonstrating the use of peripheral blood stem cells (PBSC) for autologous transplantation instead of bone marrow (BM) were performed. Subsequently, PBSC have largely supplanted BM, and are, in part, the reason for the decline in procedural related toxicity of autologous SCT [1]. In the allogeneic setting, the use of reduced-intensity conditioning (RIC), and better graft-versus-host disease (GVHD) prophylaxis has reduced treatment-related mortality (TRM).

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.